These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21165589)

  • 1. [Polypharmacy in schizophrenia].
    Zink M; Englisch S; Meyer-Lindenberg A
    Nervenarzt; 2011 Jul; 82(7):853-8. PubMed ID: 21165589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polypharmacy in schizophrenia.
    Zink M; Englisch S; Meyer-Lindenberg A
    Curr Opin Psychiatry; 2010 Mar; 23(2):103-11. PubMed ID: 20051861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polypharmacy in schizophrenia.
    Baandrup L
    Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):183-192. PubMed ID: 31908124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Optimizing the antipsychotic potency of olanzapine by augmentation--a critical review].
    Zink M
    Psychiatr Prax; 2006 Sep; 33(6):261-8. PubMed ID: 16929455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment-resistant Schizophrenia: Evidence-based Strategies.
    Englisch S; Zink M
    Mens Sana Monogr; 2012 Jan; 10(1):20-32. PubMed ID: 22654380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations.
    Lähteenvuo M; Tiihonen J
    Drugs; 2021 Jul; 81(11):1273-1284. PubMed ID: 34196945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders.
    Thompson JV; Clark JM; Legge SE; Kadra G; Downs J; Walters JT; Hamshere ML; Hayes RD; Taylor D; MacCabe JH
    J Psychopharmacol; 2016 May; 30(5):436-43. PubMed ID: 26905920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse Drug Reactions Associated with Antipsychotics, Antidepressants, Mood Stabilizers, and Stimulants.
    Givens CJ
    Nurs Clin North Am; 2016 Jun; 51(2):309-21. PubMed ID: 27229284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Polypharmacy in the treatment of schizophrenia].
    Messer T; Tiltscher C; Schmauss M
    Fortschr Neurol Psychiatr; 2006 Jul; 74(7):377-91. PubMed ID: 16804806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment.
    Längle G; Steinert T; Weiser P; Schepp W; Jaeger S; Pfiffner C; Frasch K; Eschweiler GW; Messer T; Croissant D; Becker T; Kilian R
    Acta Psychiatr Scand; 2012 May; 125(5):372-81. PubMed ID: 22321029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychotropic polypharmacy for the treatment of bipolar disorder in Taiwan.
    Hung GC; Yang SY; Chen Y; Lin SK
    Psychiatr Serv; 2014 Jan; 65(1):125-8. PubMed ID: 24382766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania.
    Miller DS; Yatham LN; Lam RW
    J Clin Psychiatry; 2001 Dec; 62(12):975-80. PubMed ID: 11780879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy in the treatment of schizophrenia.
    Wolff-Menzler C; Hasan A; Malchow B; Falkai P; Wobrock T
    Pharmacopsychiatry; 2010 Jun; 43(4):122-9. PubMed ID: 20309809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia.
    Tiihonen J; Suokas JT; Suvisaari JM; Haukka J; Korhonen P
    Arch Gen Psychiatry; 2012 May; 69(5):476-83. PubMed ID: 22566579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory processes linked to major depression and schizophrenic disorders and the effects of polypharmacy in psychiatry: evidence from a longitudinal study of 279 patients under therapy.
    Stassen HH; Bachmann S; Bridler R; Cattapan K; Herzig D; Schneeberger A; Seifritz E
    Eur Arch Psychiatry Clin Neurosci; 2021 Apr; 271(3):507-520. PubMed ID: 32696276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome.
    Jeon SW; Kim YK
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29057817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polypharmacy with second-generation antipsychotics: a review of evidence.
    Pandurangi AK; Dalkilic A
    J Psychiatr Pract; 2008 Nov; 14(6):345-67. PubMed ID: 19057237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevalence of antipsychotic polypharmacy in schizophrenic patients discharged from psychiatric units in Poland.
    Jaracz J; Tetera-Rudnicka E; Kujath D; Raczyńska A; Stoszek S; Czernaś W; Wierzbiński P; Moniakowski A; Jaracz K; Rybakowski J
    Pharmacol Rep; 2014 Aug; 66(4):613-7. PubMed ID: 24948062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation.
    Stahl SM; Grady MM
    Curr Med Chem; 2004 Feb; 11(3):313-27. PubMed ID: 14965234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.